Metabolic-Epigenetic Reprogramming in Cancer: Cell-State Plasticity, Tumor Microenvironment, and Therapeutic Opportunities

Changes in metabolism and chromatin regulation help cancer cells sustain proliferation under nutrient limitation and adapt to therapy. Acetyl-CoA and S-adenosylmethionine donate acetyl and methyl groups for histone acetylation and methylation, respectively. Other chromatin-modifying reactions require α-ketoglutarate or NAD⁺, and lactate metabolism contributes to histone lactylation. Regulation also runs in the opposite direction. DNA methylation, histone modifications, chromatin remodeling, and noncoding RNAs influence metabolic pathway use by altering expression of enzymes and transporters. These reciprocal effects can stabilize malignant cell states or alter lineage identity and substrate use, with consequences for antitumor immunity, metastatic adaptation, and drug tolerance. Accumulation of 2-hydroxyglutarate, succinate, or fumarate illustrates how metabolic perturbations can directly affect chromatin regulation and cell fate. Studies outside cancer show that some chromatin changes persist after the initiating metabolic stimulus ends. In residual disease, the question is whether cells that retain these changes after drug withdrawal respond differently to subsequent treatment than cells whose chromatin state returns to baseline. The distinction matters because a state maintained after withdrawal may present a different therapeutic target from one that requires continued drug exposure. This review examines how metabolic flux influences chromatin and how the resulting transcriptional changes shape cell states within the tumor microenvironment. We discuss clinical evidence for mutant IDH inhibition and consider investigational combinations that target metabolic and epigenetic regulators. We also examine how isotope tracing, single-cell and spatial multi-omics, and serial biomarker measurements can identify therapeutic dependencies, inform patient selection, and monitor emerging resistance.

Authors

Publication Details

Journal
Cancer Biome and Targeted Therapy
Published
2026-11-14
DOI
https://doi.org/10.66505/cbtt.v1i4.56
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Metabolic-Epigenetic Reprogramming in Cancer: Cell-State Plasticity, Tumor Microenvironment, and Therapeutic Opportunities

Yusheng Lin, Hao Zhang, Lu Wang, Piaoting Fu et al.
Cancer Biome and Targeted Therapy
Cancer, Hypoxia, and Metabolism
article

Metabolic-Epigenetic Reprogramming in Cancer: Cell-State Plasticity, Tumor Microenvironment, and Therapeutic Opportunities

Yusheng Lin, Hao Zhang, Lu Wang, Piaoting Fu, Yiling Chen
article en

Abstract

Changes in metabolism and chromatin regulation help cancer cells sustain proliferation under nutrient limitation and adapt to therapy. Acetyl-CoA and S-adenosylmethionine donate acetyl and methyl groups for histone acetylation and methylation, respectively. Other chromatin-modifying reactions require α-ketoglutarate or NAD⁺, and lactate metabolism contributes to histone lactylation. Regulation also runs in the opposite direction. DNA methylation, histone modifications, chromatin remodeling, and noncoding RNAs influence metabolic pathway use by altering expression of enzymes and transporters. These reciprocal effects can stabilize malignant cell states or alter lineage identity and substrate use, with consequences for antitumor immunity, metastatic adaptation, and drug tolerance. Accumulation of 2-hydroxyglutarate, succinate, or fumarate illustrates how metabolic perturbations can directly affect chromatin regulation and cell fate. Studies outside cancer show that some chromatin changes persist after the initiating metabolic stimulus ends. In residual disease, the question is whether cells that retain these changes after drug withdrawal respond differently to subsequent treatment than cells whose chromatin state returns to baseline. The distinction matters because a state maintained after withdrawal may present a different therapeutic target from one that requires continued drug exposure. This review examines how metabolic flux influences chromatin and how the resulting transcriptional changes shape cell states within the tumor microenvironment. We discuss clinical evidence for mutant IDH inhibition and consider investigational combinations that target metabolic and epigenetic regulators. We also examine how isotope tracing, single-cell and spatial multi-omics, and serial biomarker measurements can identify therapeutic dependencies, inform patient selection, and monitor emerging resistance.

Cancer Biome and Targeted Therapy
Cancer, Hypoxia, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon